JBM  Vol.7 No.6 , June 2019
The Physiopathological Crossroads of Aging
Abstract: Stress, inflammation and Plasminogen activator inhibitor 1 (PAI-1) are key mechanisms throughout the development of aging, constituting a crossroad in the most frequent pathologies that accompany it. Among metabolic processes, obesity, metabolic syndrome and type 2 diabetes mellitus are included and Alzheimer’s disease among the neurodegenerative processes. Stress is a mechanism of defense of the organism against exogenous and endogenous actions called stressors. In the case of low intensity stimuli, the organism responds with actions aimed at a physiological adaptation (Homeostasis). On the other hand, when a high intensity (experimental level) or chronic stimulus (oxidative stress) is repeated, structural and functional changes are observed in different organs with activation of the hypothalamus-pituitary-adrenal axis, the renin angiotensin system and the sympathetic nervous system, stimulating the production of hormones that release cytokines with proin-flammatory/antiinflammatory properties that play an important role in the previously mentioned pathologies, as well as a marked increase in PAI-1, a gene regulated by stress and by cytokines, with manifest action at the origin of thromboembolic disease, so frequent in aging. The objective of this review is to highlight the importance of the binomial stress and PAI-1 in aging and in the pathologies that accompany it. Because PAI-1 is part of the pathology and complications in aging, some authors suggest the study of PAI-1 inhibitors to achieve its physiological levels, as part of the treatment of these diseases.
Cite this paper: Lasierra-Cirujeda, J. , Coronel, P. , Pascual-Salcedo, M. , Gimeno, M. , Salcedo, M. , Lasierra-Ibañez, A. and Lasala-Aza, C. (2019) The Physiopathological Crossroads of Aging. Journal of Biosciences and Medicines, 7, 102-128. doi: 10.4236/jbm.2019.76007.

[1]   Selye, H. (1936) Syndrome Produced by Diverse Nocuous Agents. Nature, 138, 32.

[2]   Selye, H. (1946) The General Adaptation Syndrome and the Diseases of Adaptation. The Journal of Clinical Endocrinology & Metabolism, 6, 117-230.

[3]   Selye, H. (1950)) Stress and the General Adaptation Syndrome. British Medical Journal, 1, 1383-1392.

[4]   Lasierra-Cirujeda, J. (1968) Contributions to the Vascular Distribution and Topography Neurosecretory in the Surface of Pituitary Contact, as Well as Concomitant Visceral Vascularization in Connection with Experimental States of Alarm. Anales de Anatomía, 17, 485-536.

[5]   Tsigos, C. and Chrousos, G.P. (2002) Hypothalamic-Pituitary-Adrenal Axis, Neuroendocrine Factor and Stress. Journal of Psychosomatic Research, 53, 865-871.

[6]   Sterling, P. and Eyer, J. (1988) Allostasis: A New Paradigm to Explain Arousal Pathology. In: Fisher, S. and Reason, J., Eds., Handbook of Life Stress, Cognition and Health, John Wiley, New York, 629-649.

[7]   Calabrese, E.J. (2008) Stress Biology and Hormesis: The Yerkes-Dodson Law in Psychology—A Special Case of the Hormesis Dose Response. Critical Reviews in Toxicology, 38, 453-462.

[8]   Demirovic, C. and Rattan, S.I. (2013) Establishing Cellular Stress Response Profiles as Biomarkers of Hemodynamics, Health and Hormesis. Experimental Gerontology, 48, 94-98.

[9]   Karrow, N.A. (2006) Activation of the Hypothalamic-Pituitary-Adrenal Axis and Autonomic Nervous System during Inflammation and Altered Programming of Neuroendocrine-Immune Axis during Fetal and Neonatal Development: Lessons Learned from the Model Inflammagen, Lipopolysaccharide. Brain, Behavior, and Immunity, 20, 144-158.

[10]   Calabrese, E.J., Bachmann, K.A., Bailer, A.J., et al. (2007) Biological Stress Response Terminology: Integrating the Concepts of Adaptive Response and Preconditioning Stress within a Hormetic Dose-Response Framework. Toxicology and Applied Pharmacology, 122, 122-128.

[11]   Rattan, S.I. (2008) Hormesis in Aging. Ageing Research Reviews, 7, 63-78.

[12]   Rattan, S.I. (2014) Aging Is Not a Disease: Implications for Intervention. Aging and Disease, 5, 196-202.

[13]   Bernad, C. (1957) An Introduction to the Study of Experimental Medicine. Macmillan & Co. Ltd., London.

[14]   Cannon, W.B. (1932) Physiological Regulation of Normal States: Some Tentative Postulates Concerning Biological Homeostatics. In: Pettit, A., Ed., A Charles Richet: Ses amis, ses colléges, ses eléves, Les Editions Medicales, Paris, 91-93. (In French)

[15]   Davies, K.J. (2016) Adaptive Homeostasis. Molecular Aspects of Medicine, 49, 1-7.

[16]   Colucci, M., Páramo, J.A. and Collen, D. (1985) Generation in Plasma of a Fast-Acting Inhibitor of Plasminogen Activator in Response to Endotoxin Stimulation. Journal of Clinical Investigation, 75, 818-824.

[17]   Emeis, J.J. and Kooistra, T. (1986) Interleukin 1 and Lipopolysaccharide Induce an Inhibitor of Tissue-Type Plasminogen Activator in Vivo and in Cultured Endothelial Cells. The Journal of Experimental Medicine, 163, 1260-1266.

[18]   Pralong, G., Calandra, T., Glauser, M.P., Schellekens, J., et al. (1989) Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock. Thrombosis and Haemostasis, 61, 459-462.

[19]   Quax, P.H., van den Hoogen, C.M., Verheijen, J.H., Padro, T., et al. (1990) Endotoxin Induction of Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 mRNA in Rat Tissue in Vivo. The Journal of Biological Chemistry, 265, 15560-15563.

[20]   Yamamoto, K. and Loskutoff, D.J. (1996) Fibrin Deposition in Tissues from Endotoxin-Treated Mice Correlated with Decreases in the Expression of Urokinase-Type But Not Tissue-Type Plasminogen Activator. Journal of Clinical Investigation, 97, 2440-2451.

[21]   Yamamoto, K., Takeshita, K., Shimokawa, T., Yi, H., Isobe, K., et al. (2002) Plasminogen Activator Inhibitor-1 Is a Major Stress-Regulated Gene: Implications for Stress-Induced Thrombosis in Aged Individuals. Proceedings of the National Academy of Sciences of the United States of America, 99, 890-895.

[22]   Yamamoto, K., Takeshita, K., Kojima, T., Takamatsu, H. and Saito, H. (2005) Aging and Plasminogen Activator Inhibitor-1 (PAI-1) Regulation: Implication in the Pathogenesis of Thrombotic Disorder in the Elderly. Cardiovascular Research, 66, 276-285.

[23]   Black, P.H. and Garbutt, L.D. (2002) Stress, Inflammation and Cardiovascular Disease. Journal of Psychosomatic Research, 52, 1-23.

[24]   Black, P.H. (2006) The Inflammatory Consequences of Psychologic Stress: Relationship to Insulin Resistance, Obesity, Atherosclerosis and Diabetes Mellitus, Type II. Medical Hypotheses, 67, 879-891.

[25]   Bierhaus, A., Humpert, P.M. and Nawroth, P.P. (2006) Linking Stress to Inflammation. Anesthesiology Clinics, 24, 325-340.

[26]   Blake, M.J., Udelsman, R., Feulner, G.J., Norton, D.D. and Holbrook, N.J. (1991) Stress-Induced Heat Shock Protein 70 Expression in Adrenal Cortex: An Adrenocorticotropic Hormone-Sensitive, Age-Dependent Response: Proceedings of the National Academy of Sciences of the United States of America, 88, 9873-9877.

[27]   Udelsman, R., Blake, M.J., Stagg, C.A., Li, D.-G., Putney, D.J. and Holbrook, N.J. (1993) Vascular Heat Shock Protein Expression in Response to Stress. Endocrine and Autonomic Regulation of This Age-Dependent Response. Journal of Clinical Investigation, 91, 465-473.

[28]   Chin, J.H., Okazaki, M., Hu, Z.W., Miller, J.W. and Hoffman, B.B. (1996) Activation of Heat Shock Protein (HSP) 70 and Proto-Oncogene Expression by Alpha 1 Adrenergic Agonist in Rat Aorta with Age. Journal of Clinical Investigation, 97, 2316-2323.

[29]   Black, P.H. (2002) Stress and the Inflammatory Response: A Review of Neurogenic Inflammation. Brain, Behavior, and Immunity, 16, 622-653.

[30]   Black, P.H. (2003) The Inflammatory Response Is an Integral Part of the Stress Response: Implications for Atherosclerosis, Insulin Resistance, Type II Diabetes and Metabolic Syndrome X. Brain, Behavior, and Immunity, 17, 350-364.

[31]   Kiecolt-Glaser, J.K., Preacher, K.J., MacCallun, R.C., Atkinson, C., Malarkey, W.B. and Glaser, R. (2003) Chronic Stress and Age-Related Increases in the Proinflammatory Cytokine IL-6. Proceedings of the National Academy of Sciences of the United States of America, 100, 9090-9095.

[32]   Lupien, S.J., Maheu, F., Tu, M., Fiocco, A. and Schramek, T.E. (2007) The Effects of Stress and Stress Hormones on Human Cognition: Implications for the Field of Brain and Cognition. Brain and Cognition, 6, 209-237.

[33]   Forsey, R.J., Thompson, J.M., Emerudh, J., Hurst, T.L., Strindhall, J., et al. (2003) Plasma Cytokine Profiles in Elderly Humans. Mechanisms of Ageing and Development, 124, 487-493.

[34]   Sapolsky, R., Armanini, M., Packan, D. and Tombaugh, G. (1987) Stress and Glucocorticoids in Aging. Endocrinology & Metabolism Clinics of North America, 16, 965-980.

[35]   Stein-Behrens, B.A. and Sapolsky, R.M. (1992) Stress, Glucocorticoids, and Aging. Aging (Milano), 4, 197-210.

[36]   Eren, M., Boe, A.E., Murphy, S.B., Place, A.T., Nagpal, V., et al. (2014) PAI-1-Regulated Extracellular Proteolysis Governs Senescence and Survival in Klotho Mice. Proceedings of the National Academy of Sciences of the United States of America, 111, 7090-7095.

[37]   Holliday, R. (2006) Aging Is No Longer an Unsolved Problem in Biology. Annals of the New York Academy of Sciences, 1067, 1-9.

[38]   Liochev, S.I. (2015) Reflections on the Theories of Aging, of Oxidative Stress and of Science in General. Is It Time to Abandon the Free Radical Theory of Aging? Antioxidants & Redox Signaling, 23, 187-207.

[39]   Harman, D. (1956) Aging: A Theory Based on Free Radical and Radiation Chemistry. The Journals of Gerontology, 11, 298-300.

[40]   Knight, J.A. (2000) The Biochemistry of Aging. Advances in Clinical Chemistry, 35, 1-62.

[41]   Vi?a, J., Borrás, C. and Miquel, J. (2007) Theories of Ageing. Life, 59, 249-254.

[42]   Liochev, S.I. (2013) Reactive Oxygen Species and the Free Radical Theory of Aging. Free Radical Biology & Medicine, 60, 1-4.

[43]   Moskalev, A.A., Aliper, A.M., Smit-McBride, Z., Buzdin, A. and Zhavoronkov, A. (2014) Genetics and Epigenetics of Aging and Longevity. Cell Cycle, 13, 1063-1077.

[44]   Rattan, S.I. and Clark, B.F. (2005) Understanding and Modulating Ageing. Life, 57, 297-304.

[45]   Rattan, S.I. (2012) Biogerontology: From Here to Where? The Lord Cohen Medal Lecture-2011. Biogerontology, 13, 83-91.

[46]   Rattan, S.I. (2013) Healthy Ageing, But What Is Health? Biogerontology, 14, 673-677.

[47]   Campisi, J. and d’Adda di Fagagna, F. (2007) Cellular Senescence: When Bad Thing Happens to Good Cells. Nature Reviews Molecular Cell Biology, 8, 729-740.

[48]   Campisi, J. (2013) Aging, Cellular Senescence, and Cancer. Annual Review of Physiology, 75, 665-705.

[49]   Parsons, P.A. (2000) Hormesis: An Adaptive Expectation with Emphasis on Ionizing Radiation. Journal of Applied Toxicology, 20, 103-112.<103::AID-JAT639>3.0.CO;2-O

[50]   Calabrese, E.J. and Baldwin, L.A. (2000) Tales of Two Similar Hypotheses: The Rise and Fall of Chemical and Radiation Hormesis. Human & Experimental Toxicology, 19, 85-97.

[51]   Kimura, K., Tanaka, N., Nakamura, N., Takano, S. and Ohkuma, S. (2007) Knockdown of Mitochondrial Heat Shock Protein 70 Promotes Progeria-Like Phenotypes in Caenorhabditis Elegans. The Journal of Biological Chemistry, 282, 5010-5018.

[52]   Mattson, M.P. (2008) Hormesis Defined. Ageing Research Reviews, 7, 1-7.

[53]   Gems, D. and Partridge, L. (2008) Stress-Response Hormesis and Aging: “That Which Does Not Kill Us Makes Us Stronger”. Cell Metabolism, 7, 200-203.

[54]   Van Raamsdonk, J.M. and Hekimi, S. (2011) FUdR Causes a Twofold Increase in the Lifespan of the Mitochondrial Mutant Gas-1. Mechanisms of Ageing and Development, 132, 519-521.

[55]   Li, W.H., Shi, Y.C., Chang, C.H., Huang, C.W., et al. (2014) Selenite Protects Caenorhabditis elegans from Oxidative Stress via DAF-16 and TRXR-1. Molecular Nutrition & Food Research, 58, 863-874.

[56]   Bansal, A., Zhu, L.J., Yen, K. and Tissenbaum, H.A. (2015) Uncoupling Lifespan and Health Span in Caenorhabditis elegans Longevity Mutants. Proceedings of the National Academy of Sciences of the United States of America, 112, E277-E286.

[57]   Dues, D.J., Andrews, E.K., Schaar, C.E., Bergsma, A.L., Senchuk, M.M. and Van Raamsdonk, J.M. (2016) Aging Causes Decreased Resistance to Multiple Stresses and a Failure to Activate Specific Stress Response Pathways. Aging (Albany NY), 8, 777-795.

[58]   Liu, H., Wang, H., Shenvi, S., Hagen, T.M. and Liu, R.M. (2004) Glutathione Metabolism during Aging and in Alzheimer Disease. Annals of the New York Academy of Sciences, 1019, 346-349.

[59]   Patel, R., Mcintosh, L., Mclaughlin, J., Brooke, S., Nimon, V. and Salpolsky, R. (2002) Disruptive Effects of Glucocorticoids on Glutathione Peroxidase Biochemistry in Hippocampal Cultures. Journal of Neurochemistry, 82, 118-125.

[60]   Miller, D.B. and O’Callaghan, J.P. (2005) Aging, Stress and the Hippocampus. Ageing Research Reviews, 4, 123-140.

[61]   Dringen, R. (2000) Metabolism and Functions of Glutathione in Brain. Progress in Neurobiology, 62, 649-671.

[62]   Lasierra-Cirujeda, J., Aza Pascual-Salcedo, M.J., Lasierra-Ibanez, A., Lasala-Aza, C. and Aza Pascual-Salcedo, M.M. (2016) Aging: Thromboembolic Disease, Metabolic syndrome, Type 2 Diabetes Mellitus, and Alzheimer’s Disease. Journal of Biosciences and Medicine, 4, 1-20.

[63]   Stohs, S.J., Lawson, T. and Al-Turk, W.A. (1984) Changes in Glutathione and Glutathione Metabolizing Enzymes in Erythrocytes and Lymphocytes of Mice as a Function of Age. General Pharmacology, 15, 267-270.

[64]   Lang, C.A., Naryshkin, S., Schneider, D.L., Mills, B.J. and Lindeman, R.D. (1992) Low Blood Glutathione Levels in Healthy Aging Adults. Journal of Laboratory and Clinical Medicine, 120, 720-725.

[65]   Julius, M., Lang, C.A., Gleiberman, L., Harburg, E., DiFranceisco, W. and Schork, A. (1994) Glutathione and Morbidity in a Community-Based Sample of Elderly. Journal of Clinical Epidemiology, 47, 1021-1026.

[66]   Samiec, P.S., Drews-Botsch, C., Flagg, E.W., Kurtz, J.C., Stemberg, P., Reed, R.L. and Jones, D.P. (1998) Glutathione in Human Plasma: Decline in Association with Aging, Age-Related Macular Degeneration, and Diabetes. Free Radical Biology & Medicine, 24, 699-704.

[67]   Rebrin, I. and Sohal, R.S. (2008) Pro-Oxidant Shift in Glutathione Redox State during Aging. Advanced Drug Delivery Reviews, 60, 1545-1552.

[68]   Sekhar, R.V., Patel, S.G., Guthikonda, A.P., Reid, M., Balasubramanyam, A., Taffet, G.E. and Jahoor, F. (2011) Deficient Synthesis of Glutathione Underlies Oxidative Stress in Aging and Can Be Corrected by Dietary Cysteine and Glycine Suppplementation. The American Journal of Clinical Nutrition, 94, 847-853.

[69]   Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Jenner, P. and Marsden, C.D. (1994) Glutathione-Related Enzymes in Brain in Parkinson’s Disease. Annals of Neurology, 36, 356-361.

[70]   Schulz, J.B., Lindenau, J., Seyfried, J. and Dichgans, J. (2000) Glutathione, Oxidative Stress and Neurodegeneration. European Journal of Biochemistry, 267, 4904-4911.

[71]   Rahman, I. and MacNee, W. (2000) Oxidative Stress and Regulation of Glutathione in Lung Inflammation. European Respiratory Society, 16, 534-554.

[72]   Stadtman, E.R. (1992) Protein Oxidation and Aging. Science, 257, 1220-1224.

[73]   Guidi, I., Galimberti, D., Lonati, S., Novembrino, C., Bamonti, F., Tiriticco, M., et al. (2006) Oxidative Imbalance in Patients with Mild Cognitive Impairment and Alzheimer’s Disease. Neurobiology of Aging, 27, 262-269.

[74]   Yu, B.P. and Chung, H.Y. (2006) Adaptive Mechanism to Oxidative Stress during Aging. Mechanisms of Ageing and Development, 127, 436-443.

[75]   Schafer, F.Q. and Buettner, G.R. (2001) Redox Environment of the Cell as Viewed through the Redox State of Glutathione Disulfide/Glutathione Couple. Free Radical Biology & Medicine, 30, 1191-1212.

[76]   Mytilineou, C., Kramer, B.C. and Yabut, J.A. (2002) Glutathione Depletion and Oxidative Stress. Parkinsonism & Related Disorders, 8, 385-387.

[77]   Lasierra-Cirujeda, J., Coronel, P., Aza, M.J. and Gimeno, M. (2013) Beta-Amyloidosis and the Glutathione in Alzheimer’s Disease. Journal of Blood Medicine, 4, 31-38.

[78]   Zhang, H., Davies, K.J.A. and Forman, H.J. (2015) Oxidative Stress Response and Nrf2 Signaling in Aging. Free Radical Biology & Medicine, 88, 314-336.

[79]   Butterfield, D.A., Yatin, S.M., Varadajaran, S. and Koppal, T. (1999) Amyloid β-Peptide-Associated Free Radical Oxidative Stress, Neurotoxicity, and Alzheimer’s Disease. Methods in Enzymology, 309, 746-768.

[80]   Varadarajaran, S., Yatin, S., Aksenova and Butterfield, D.A. (2000) Review: Alzheimer’s Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity. Journal of Structural Biology, 130, 184-208.

[81]   Butterfield, D.A. (2002) Amyloid β-Peptide (1-42)-Induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer’s Disease Brain. A Review. Free Radical Research, 36, 1307-1313.

[82]   Butterfield, D.A., Perluigi, M. and Sultana, R. (2006) Oxidative Stress in Alzheimer’s Disease Brain: New Insights from Redox Proteomics. European Journal of Pharmacology, 545, 39-50.

[83]   Cachofeiro, V., Goicochea, M., de Vinuesa, S.G., Oubi?a, P., Lahera, V. and Lu?o, J. (2008) Oxidative Stress and Inflammation, a Link between Chronic Kidney Disease and Cardiovascular Disease. Kidney International Supplements, 111, S4-S9.

[84]   Tucker, P.S., Scanlan, A.T. and Dalbo, V.J. (2015) Chronic Kidney Disease Influences Multiple Systems: Describing the Relationship between Stress, Inflammation, Kidney Damage, and Concomitant Disease. Oxidative Medicine and Cellular Longevity, 2015, Article ID: 806358.

[85]   Kumar-Biswas, S. (2016) Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox? Oxidative Medicine and Cellular Longevity, 2016, Article ID: 5698931.

[86]   Kohler, H.-P. (2002) Insulin Resistance Syndrome: Interaction with Coagulation and Fibrinolysis. Swiss Medical Weekly, 132, 241-252.

[87]   Hubert, H.B., Feinleib, M., McNamara, P.M. and Castelli, W.P. (1983) Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26-Year Follow-Up of Participants in the Framingham Heart Study. Circulation, 67, 968-977.

[88]   Juhan-Vague, I. and Alessi, M.C. (1997) PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events. Thrombosis and Haemostasis, 78, 656-660.

[89]   Mokdad, A.H., Serdula, M.K., Dietz, W.H., Bowman, B.A., Marks, J.S. and Koplan, J.P. (1999) The Spread of the Obesity Epidemic in United States, 1991-1998. JAMA, 282, 1519-1522.

[90]   Ceriello, A. and Motz, E. (2004) Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 816-823.

[91]   Grant, P.J. (2007) Diabetes Mellitus as a Prothrombotic Condition. Journal of Internal Medicine, 262, 157-172.

[92]   Kyrou, I. and Tsigos, C. (2007) Stress Mechanisms and Metabolic Complications. Hormone and Metabolic Research, 39, 430-438.

[93]   Alessi, M.C. and Juhan-Vague, I. (2008) Metabolic Syndrome, Haemostasis and Thrombosis. Thrombosis and Haemostasis, 99, 995-1000.

[94]   Grundy, S.M. (2008) Metabolic Syndrome Pandemic. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 629-636.

[95]   Tsugane, S. and Inoue, M. (2010) Insulin Resistance and Cancer: Epidemiological Evidence. Cancer Science, 101, 1073-1079.

[96]   Rohleder, N. (2014) Stimulation of Systemic Low-Grade In-flammation by Psychosocial Stress. Psychosomatic Medicine, 76, 181-189.

[97]   Athauda, D. and Foltynie, T. (2016) Insulin Resistance and Parkinson’s Disease: A New Target for Disease Modification? Progress in Neurobiology, 145-146, 98-120.

[98]   Lavretsky, H. and Newhouse, P.A. (2012) Stress, Inflammation and Aging. The American Journal of Geriatric Psychiatry, 20, 729-733.

[99]   Arterbum, D.E., Crane, P.K. and Sullivan, S.D. (2004) The Coming Epidemic of Obesity in Elderly Americans. Journal of the American Geriatrics Society, 52, 1907-1912.

[100]   Mathus-Vliegen, E.M. (2012) Obesity and the Elderly. Journal of Clinical Gastroenterology, 46, 533-544.

[101]   Gallus, S., Lugo, A., Murisic, B., Bosetti, C., Boffetta, P. and La Vecchia, C. (2015) Overweight and Obesity in 16 European Countries. European Journal of Nutrition, 54, 679-689.

[102]   Coppack, S.W. (2001) Pro-Inflammatory Cytokines and Adipose Tissue. Proceedings of the Nutrition Society, 60, 349-356.

[103]   Kyrou, I., Chrousos, G.P. and Tsigos, C. (2006) Stress, Visceral Obesity, and Metabolic Complications. Annals of the New York Academy of Sciences, 1083, 77-110.

[104]   Kyrou, I. and Tsigos, C. (2009) Stress Hormones: Physiological Stress and Regulation of Metabolism. Current Opinion in Pharmacology, 9, 787-793.

[105]   Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. and Friedman, J.M. (1994) Positional Cloning of the Mouse Obese Gene and Its Human Homologue. Nature, 372, 425-432.

[106]   Mohamed-Ali, V., Pinkney, J.H. and Coppack, S.W. (1998) Adipose Tissue as an Endocrine and Paracrine Organ. International Journal of Obesity and Related Metabolic Disorders, 22, 1145-1158.

[107]   Gabay, C. and Kushner, I. (1999) Acute-Phase Proteins and Other Systemic Responses to Inflammation. The New England Journal of Medicine, 340, 448-454.

[108]   Mertens, I. and Van Gaal, L.F. (2002) Obesity, Haemostasis, and the Fibrinolytic System. Obesity Reviews, 3, 85-101.

[109]   Prins, J.B. (2002) Adipose Tissue as an Endocrine Organ. Best Practice & Research: Clinical Endocrinology & Metabolism, 16, 639-651.

[110]   Renehan, A.G., Tyson, M., Egger, M., Heller, R.F. and Zwahlen, M. (2008) Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies. The Lancet, 371, 569-578.

[111]   Parr, C.L., Batty, G.D., Lam, T.H., Barzi, F., Fang, X., Ho, S.C., et al. (2010) Body-Mass Index and Cancer Mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled Analyses of 424,519 Participants. The Lancet Oncology, 11, 741-752.

[112]   Galic, S., Oakhill, J.S. and Steinberg, G.R. (2010) Adipose Tissue as an Endocrine Organ. Molecular and Cellular Endocrinology, 316, 129-139.

[113]   Yang, W.-S., Lee, W.-J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.L., Chen, C.L., Tai, T.Y. and Chuang, L.M. (2001) Weight Reduction Increases Plasma Levels of and Adipose-Derived Anti-Inflammatory Protein, Adiponectin. The Journal of Clinical Endocrinology & Metabolism, 86, 3815-3819.

[114]   Doyle, S.L., Donohoe, C.L. and Reynolds, J.V. (2012) Visceral Obesity, Metabolic Syndrome, Insulin Resistance and Cancer. Proceedings of the Nutrition Society, 71, 181-189.

[115]   Uchida, Y., Takeshita, K., Yamamoto, K., Kikuchi, R., Nakayama, T., Nomura, M., et al. (2012) Stress Augments Insulin Resistance and Prothrombotic State: Role of Visceral Adipose-Derived Monocyte Chemoattractant Protein-1. Diabetes, 61, 1552-1561.

[116]   Brinkley, T.E., Hsu, F.C., Beavers, K.M., Church, T.S., Goodpaster, B.H., Stafford, R.S., Pahor, M., Krichevsky, S.B. and Nicklas, B.J. (2012) Total and Abdominal Adiposity Are Associated with Inflammation in Older Adults Using a Factor Analysis Approach. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 67, 1099-1106.

[117]   Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., et al. (2004) Increased Oxidative Stress in Obesity and Its Impact on Metabolic Syndrome. Journal of Clinical Investigation, 114, 1752-1761.

[118]   Cowey, S. and Hardey, R.W. (2006) The Metabolic Syndrome: A High-Risk State for Cancer? The American Journal of Pathology, 169, 1505-1522.

[119]   Wellen, K.E. and Hotamisligil, G.S. (2005) Inflammation, Stress, and Diabetes. Journal of Clinical Investigation, 115, 1111-1119.

[120]   Karastergiou, K. and Mohamed-Ali, V. (2010) The Autocrine and Paracrine Roles of Adipokines. Molecular and Cellular Endocrinology, 318, 69-78.

[121]   Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., Pollak, M., et al. (2010) Diabetes and Cancer: A Consensus Report. Diabetes Care, 33, 1674-1685.

[122]   Arcidiacono, B., Liritano, S., Nocera, A., et al. (2012) Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Experimental Diabetes Research, 2012, Article ID: 789174.

[123]   Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G. and Arrigo, T. (2014) Oxidative Stress in Obesity: A Critical Component in Human Diseases. International Journal of Molecular Sciences, 16, 378-400.

[124]   Michaud, M., Balardy, L., Moulis, G., Gaudin, C., Peyrot, C., Vellas, B., Cesari, M. and Nourhashemi, F. (2013) Proinflammatory Cytokines, Aging, and Age-Related Diseases. Journal of the American Medical Directors Association, 14, 877-882.

[125]   Pedersen, B.K., Bruunsgaard, H., et al. (2000) Cytokines in Aging and Exercise. International Journal of Sports Medicine, 1, S4-S9.

[126]   Bruunsgaard, H., Pedersen, M. and Pedersen, B.K. (2001) Aging and Proinflammatory Cytokines. Current Opinion in Hematology, 8, 131-136.

[127]   Brüünsgaard, H. and Pedersen, B.K. (2003) Age-Related Inflammatory Cytokines and Disease. Immunology and Allergy Clinics of North America, 23, 15-39.

[128]   Krabbe, K.S., Pedersen, M. and Brüünsgaard, H. (2004) Inflammatory Mediators in the Elderly. Experimental Gerontology, 39, 687-699.

[129]   Alvarez-Rodríguez, L., López-Hoyos, M., Munoz-Cacho, P. and Martínez Taboada, V.M. (2012) Aging Is Associated with Circulating Cytokine Dysregulation. Cellular Immunology, 273, 124-132.

[130]   Sikaris, K.A. (2004) The Clinical Biochemistry of Obesity. The Clinical Biochemist Reviews, 25, 165-181.

[131]   Kershaw, E.E. and Flier, J.S. (2004) Adipose Tissue as an Endocrine Organ. The Journal of Clinical Endocrinology & Metabolism, 89, 2548-2556.

[132]   Frayn, K.N., Karpe, F., Fielding, B.A., Macdonald, I.A. and Coppack, S.W. (2003) Integrative Physiology of Human Adipose Tissue. International Journal of Obesity and Related Metabolic Disorders, 27, 875-888.

[133]   Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P. and Bahouth, S.W. (2004) Comparison of the Release of Adipokines by Adipose Tissue, Adipose Tissue Matrix, and Adipocytes from Visceral and Subcutaneous Abdominal Adipose Tissues of Obese Humans. Endocrinology, 145, 2273-2282.

[134]   Cristancho, A.G. and Lazar, M.A. (2011) Forming Functional Fat: A Growing Understanding of Adipocyte Differentiation. Nature Reviews Molecular Cell Biology, 12, 722-734.

[135]   Hostamisliging, G.S., Shargill, N.S. and Spiegelman, B.N. (1993) Adipose Expression of Tumor Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance. Science, 259, 87-91.

[136]   Reaven, G.M. (1988) Banting Lecture 1988. Role of Insulin Resistance in Human Disease. Diabetes, 37, 1595-1607.

[137]   Kahn, B.B. and Flier, J.S. (2000) Obesity and Insulin Resistance. Journal of Clinical Investigation, 106, 473-481.

[138]   Kaur, J. (2014) A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice, 2014, Article ID: 943162.

[139]   Reaven, G.M., Lithell, H. and Landsberg, L. (1996) Hypertension and Associated Metabolic Abnormalities: The Role of Insulin Resistance and the Sympathoadrenal System. The New England Journal of Medicine, 334, 374-381.

[140]   Goossens, G.H. (2008) The Role of Adipose Tissue Dysfunction in the Pathogenesis of Obesity-Related Insulin Resistance. Physiology & Behavior, 94, 206-218.

[141]   Juhan-Vague, I., Alessi, M.C. and Vague, P. (1991) Increased Plasma Plasminogen Activator Inhibitor 1 Levels. A Possible Link between Insulin Resistance and Atherothrombosis. Diabetologia, 34, 457-462.

[142]   Mertens, I., Verrijken, A., Michiels, J.J., Van der Planken, M., Ruige, J.B. and Van Gaal, L.F. (2006) Among Inflammation and Coagulation Markers, PAI-1 Is a True Component of the Metabolic Syndrome. International Journal of Obesity, 30, 1308-1314.

[143]   Bastard, J.P., Maachi, M., Lagathu, C., et al. (2006) Recent Advances in the Relationship between Obesity, Inflammation, and Insulin Resistance. European Cytokine Network, 17, 4-12.

[144]   Kim, C.S., Park, H.S., Kawada, T., Kim, J.H., Lim, D., Hubbard, N.E., et al. (2006) Circulating Levels of MCP-1 and IL-8 Are Elevated in Human Obese Subjects and Associated with Obesity-Related Parameters. International Journal of Obesity, 30, 1347-1355.

[145]   Rabe, K., Lehrke, M., Parhofer, K.G. and Broedl, U.C. (2008) Adipokines and Insulin Resistance. Molecular Medicine, 14, 741-751.

[146]   Antuna-Puente, B., Feve, B., Fellahi, S. and Bastard, J.P. (2008) Adypokines: The Missing Link between Insulin Resistance and Obesity. Diabetes & Metabolism, 34, 2-11.

[147]   Loskutoff, D.J. and Samad, F. (1998) The Adipocyte and Hemostatic Balance in Obesity: Studies of PAI. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 1-6.

[148]   Bastard, J.P. and Piéroni, J. (1999) Plasma Plasminogen Activator Inhibitor 1, Insulin Resistance and Android Obesity. Biomedicine & Pharmacotherapy, 53, 455-461.

[149]   Matsuzawa, Y., Funahashi, T. and Nakamura (1999) Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines Adipocyte-Derived Bioactive Substances. Annals of the New York Academy of Sciences, 892, 146-154.

[150]   Skurk, T. and Hauner, H. (2004) Obesity and Impaired Fibrinolysis: Role of Adipose Production of Plasminogen Activator Inhibitor-1. International Journal of Obesity and Related Metabolic Disorders, 28, 1357-1364.

[151]   You, A., Nicklas, B.J., Ding, J., Pennix, B.W., Goodpaster, B.H., Bauer, D.C., et al. (2008) The Metabolic Syndrome Is Associated with Circulating Adipokines in Older Adults across a Wide Range of Adiposity. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 63, 414-419.

[152]   Shimomura, I., Funahashi, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., et al. (1996) Enhanced Expression of PAI-1 in Visceral Fat: Possible Contributor to Vascular Disease in Obesity. Nature Medicine, 2, 800-803.

[153]   Jugan-Vague, I., Morange, P.E. and Alessi, M.C. (2002) The Insulin Resistance Syndrome: Implications for Thrombosis and Cardiovascular Disease. Pathophysiology of Haemostasis and Thrombosis, 32, 269-273.

[154]   Ford, E.S. (2004) The Metabolic Syndrome and Mortality from Cardiovascular Disease and All-Causes: Finding from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis, 173, 309-314.

[155]   Alberti, K.G., Zimmet, P. and Shaw, J. (2005) The Metabolic Syndrome—A New Worldwide Definition. The Lancet, 366, 1059-1062.

[156]   Morange, P.E., Saut, N., Alessi, M.C., Yudkin, J.S., Margaglione, M., Di Minno, G., et al. (2007) Association of Plasminogen Activator Inhibitor (PAI-1) (SERPINE 1) SNPs with Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 2250-2257.

[157]   Odrowaz-Sypniewska, G. (2007) Markers of Pro-Inflammatory and Pro-Thrombotic State in the Diagnosis of Metabolic Syndrome. Advances in Medical Sciences, 52, 246-250.

[158]   Alessi, M.C., Poggi, M. and Jugan-Vague, I. (2007) Plasminogen Activator Inhibitor-1, Adipose Tissue and Insulin Resistance. Current Opinion in Lipidology, 18, 240-245.

[159]   Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645.

[160]   Dentali, F., Squizzato, A. and Ageno, W. (2009) The Metabolic Syndrome as a Risk Factor for Venous and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 35, 451-457.

[161]   Himsworth, H.P. (1936) Management of Diabetes Mellitus. British Medical Journal, 2, 188-190.

[162]   Shen, S.W., Reaven, G.M. and Farquhar, J.W. (1970) Comparison of Impedance to Insulin-Mediated Glucose Uptake in Normal Subjects and in Subjects with Latent Diabetes. Journal of Clinical Investigation, 49, 2151-2160.

[163]   Fink, R.I., Kolterman, O.G., Griffin, J. and Olefsky, J.M. (1983) Mechanisms of Insulin Resistance in Aging. Journal of Clinical Investigation, 71, 1523-1535.

[164]   Weiderpass, E., Gridley, G., Nyren, O., Ekbom, A., Persson, I. and Adami, H.O. (1997) Diabetes Mellitus and Risk of Large Bowel Cancer. Journal of the National Cancer Institute, 89, 660-661.

[165]   Jee, S.H., Ohrr, H., Sull, J.W., Yun, J.E., Ji, M. and Samet, J.M. (2005) Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women. JAMA, 293, 194-202.

[166]   Neth, B.J. and Craft, S. (2017) Insulin Resistance and Alzheimer’s Disease: Bionergetic Linkages. Frontiers in Aging Neuroscience, 9, 345.

[167]   Meigs, J.B., Larson, M.G., Fox, C.S., Keaney, J.F., Vasan, R.S. and Benjamin, E.J. (2007) Association of Oxidative Stress, Insulin Resistance, and Diabetes Risk Phenotypes: The Framingham Offspring Study. Diabetes Care, 30, 2529-2535.

[168]   Gopaul, N.K., Angg?rd, E.E., Maller, A.I., Betteridge, D.J., Wolff, S.P. and Nourooz-Zadeh, J. (1995) Plasma 8-epi-PGF2 Alpha Levels Are Elevated in Individuals with Non-Insulin Dependent Diabetes Mellitus. FEBS Letters, 368, 225-229.

[169]   Abbasian, M., Delvarianzadeh, M., Ebrahim, H., Khosravi, F. and Nourozi, P. (2018) Relationship between Serum Levels of Oxidative Stress and Metabolic Syndrome Components. Diabetes & Metabolic Syndrome, 12, 497-500.

[170]   Schmidt, M.I., Duncan, B.B., Sharrett, A.R., Lindberg, G., Savage, P.J., Offenbacher, S., Azambuja, M.I., Tracy, R.P. and Heiss, G. (1999) Markers of Inflammation and Prediction of Diabetes Mellitus in Adults (Atherosclerosis Risk in Communities Study, a Cohort Study). The Lancet, 353, 52.

[171]   Pickup, J.C. and Crook, M.A. (1998) Is Type II Diabetes Mellitus a Disease of the Innate Immune System? Diabetologia, 41, 1241-1248.

[172]   Greenfild, J.R. and Campbell, L.V. (2006) Relationship between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect? Current Diabetes Reviews, 2, 195-211.

[173]   Pan, W.H., Cedres, L.B., Liu, K., Dyer, A., Schoenberger, J.A., Shelkelle, R.B., Stamier, R., et al. (1986) Relationship of Clinical Diabetes and Asymptomatic Hyperglycemia to Risk of Coronary—Heart Disease Mortality in Men and Women. American Journal of Epidemiology, 123, 504-516.

[174]   Auwerx, J., Bouillon, R., Collen, D. and Geboers, J. (1988) Tissue-Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus. Arteriosclerosis, 8, 68-72.

[175]   Uusitupa, M.I., Niskanen, L.K., Siitonen, O., Voutilainen, E. and Pyorala, K. (1990) 5-Year Incidence of Atherosclerotic Vascular Disease in Relation to General Risk Factors, Insulin Level, and Abnormalities in Lipoprotein Composition in Non-Insulin-Dependent Diabetic and Nondiabetic Subjects. Circulation, 82, 27-36.

[176]   Schneider, D.J., Nordt, T.K. and Sobel, B.E. (1993) Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients. Diabetes, 42, 1-7.

[177]   Urano, T., Kojima, Y., Takahashi, M., Serizawa, K., Sakakibara, K., Takada, Y. and Takada, A. (1993) Impaired Fibrinolysis in Hypertension and Obesity Due to High Plasminogen Activator Inhibitor-1 Level in Plasma. The Japanese Journal of Physiology, 43, 221-228.

[178]   Fujii, S., Goto, D., Zaman, T., Ishimori, N., Watano, K., Kaneko, T., Okada, H., Makiguchi, M., Nakawana, T. and Kitabatake, A. (1998) Diminished Fibrinolysis and Thrombosis: Clinical Implications for Accelerated Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 5, 76-81.

[179]   Lyon, C.J. and Hsueh, W.A. (2003) Effect of Plasminogen Activator In-hibitor-1 in Diabetes Mellitus and Cardiovascular Disease. The American Journal of Medicine, 8, 62S-68S.

[180]   Jung, R.G., Motazedian, P., Ramirez, F.D., Di Santo, P., Visintini, S., Faraz, M.A., Labinaz, A., Jung, Y., et al. (2018) Association between Plasminogen Activator Inhibitor-1 and Cardiovascular Events: A Systematic Review and Meta-Analysis. Thrombosis Journal, 16, 12.

[181]   Esch, T., Stefano, G.B., Fricchione, G.L. and Benson, H. (2002) The Role of Stress in Neurodegenerative Diseases and Mental Disorders. Neuro Enocrinology Letters, 23, 199-208.

[182]   Everson-Rose, S.A., Mendes de Leon, C.F., Bienias, J.L., Wilson, R.S. and Evans, D.A. (2003) Early Life Conditions and Cognitive Functioning in Later Life. American Journal of Epidemiology, 158, 1083-1089.

[183]   Brunson, K.L., Kramar, E., Lin, B., Chen, Y., Colgin, L.L., Yanagihara, T.K., Lynch, G. and Baram, T.Z. (2005) Mechanism of Late-Onset Cognitive Decline after Early-Life Stress. Journal of Neuroscience, 25, 9328-9338.

[184]   Chen, Y. and Baram, T.Z. (2016) Toward Understanding How Early-Life Stress Reprograms Cognitive and Emotional Brain Networks. Neuropsychopharmacology, 41, 197-206.

[185]   Vyas, S., Rodrigues, A.J., Silva, J.M., Tronche, F., Almeida, O.F., Sousa, N. and Sotiropoulos, I. (2016) Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. Neural Plasticity, 2016, Article ID: 6391686.

[186]   Swaab, D.F., Bao, A.M. and Lucassen, P.J. (2005) The Stress System in the Human Brain in Depression and Neurodegeneration. Ageing Research Reviews, 4, 141-194.

[187]   Nair, A. and Bonneau, R.H. (2006) Stress-Induced Elevation of Glucocorticoids Increases Microglia Proliferation through NMDA Receptor Activation. Journal of Neuroimmunology, 171, 72-85.

[188]   Frank, M.G., Thompson, B.M., Watkins, L.R. and Maler, S.F. (2012) Glucocorticoids Mediate Stress-Induced Priming of Microglial Pro-Inflammatory Responses. Brain, Behavior, and Immunity, 26, 337-345.

[189]   Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C. and Scheltens, P. (2006) Risk of Dementia in Diabetes Mellitus: A Systematic Review. The Lancet Neurology, 5, 64-74.

[190]   Ott, A., Stolk, R.P., Hofman, A., van Harskamp, F., Grobbee, D.E. and Breteler, M.M. (1996) Association of Diabetes Mellitus and Dementia: The Rotterdam Study. Diabetologia, 39, 1392-1397.

[191]   Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., Breteler, M.M., et al. (1999) Diabetes Mellitus and the Risk of Dementia: The Rotterdam Study. Neurology, 53, 1937-1942.

[192]   Janson, J., Laedke, T., Parisi, J.E., O’Brien, P., Petersen, R.C. and Butler, P.C. (2004) Increase Risk of Type 2 Diabetes in Alzheimer Disease. Diabetes, 53, 474-481.

[193]   Hüll, M., Strauss, S., Berger, M., Volk, N. and Bauer, J. (1996) Inflammatory Mechanisms in Alzheimer’s Disease. European Archives of Psychiatry and Clinical Neuroscience, 246, 124-128.

[194]   Aisen, P.S. (1997) Inflammation and Alzheimer’s Disease: Mechanisms and Therapeutic Strategies. Gerontology, 43, 143-149.

[195]   Neuroinflammation Working Group, Akiyama, H., Barger, S., Barnum, S., et al. (2000) Inflammation and Alzheimer’s Disease. Neurobiology of Aging, 21, 383-421.

[196]   Tuppo, E.E. and Arias, H.R. (2005) The Role of Inflammation in Alzheimer’s Disease. The International Journal of Biochemistry & Cell Biology, 37, 289-305.

[197]   Swardfager, W., Lanct?t, K., Rothenburg, L., Wong, A., Cappell, J. and Hermann, N. (2010) A Meta-Analysis of Cytokines in Alzheimer’s Disease. Biological Psychiatry, 68, 930-941.

[198]   Stauss, D.S., Bauer, J., Ganter, U., Jonas, U., Jpnas, U., Berger, M. and Volk, B. (1992) Detection of Interleukin-6 and Alpha 2-Macroglobulin Immunoreactivity in Cortex and Hippocampus of Alzheimer’s Disease Patients. Laboratory Investigation, 66, 223-230.

[199]   Altstiel, L.D. and Sperber, K. (1991) Cytokines in Alzheimer’s Disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 15, 481-495.

[200]   Del Bo, R., Angeretti, N., Lucca, E., De Simoni, M.G. and Forloni, G. (1995) Reciprocal Control of Inflammatory Cytokines, IL-1 and IL-6, and Beta-Amyloid Production in Cultures. Neuroscience Letters, 188, 70-74.

[201]   Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H. and Riederer, P. (1995) Interleukin-1β and Interleukin-6 Are Elevated in the Cerebrospinal Fluid of Alzheimer’s and de novo Parkinson’s Disease Patients. Neuroscience Letters, 202, 17-20.

[202]   Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M. and Ihara, Y. (1988) A Variety of Cerebral Amyloid Deposits in the Brains of the Alzheimer-Type Dementia Demonstrated by β Protein Immunostaining. Acta Neuropathologica, 76, 541-549.

[203]   Tagliavini, F., Giaccone, G., Frangione, B. and Bugiani, O. (1988) Preamyloid Deposits in the Cerebral Cortex of Patients with Alzheimer’s Disease and Nondemented Individuals. Neuroscience Letters, 93, 191-196.

[204]   Hull, M., Strauss, S., Volk, B., Berger, M. and Bauer, J. (1995) Interleukin-6 Is Present in Early Stages of Plaque Formation and Is Restricted to the Brain of Alzheimer’s Disease Patients. Acta Neuropathologica, 89, 544-551.

[205]   Griffin, M., Strauss, S., Volk, B., Berger, M. and Bauer, J. (1995) Interleukin-1 Expression in Different Plaque Types in Alzheimer’s Disease: Significance in Plaque Evolution. Journal of Neuropathology & Experimental Neurology, 54, 276-281.

[206]   Griffin, W.S. and Mrak, R.E. (2002) Interleukin-1 in the Genesis and Progression of and Risk for Development of Neuronal Degeneration in Alzheimer’s Disease. Journal of Leukocyte Biology, 72, 233-238.

[207]   Nathan, C. (2002) Points of Control in Inflammation. Nature, 420, 846-852.

[208]   Hanisch, U.K. and Kettenmann, H. (2007) Microglia: Active Sensor and Versatile Effector Cells in the Normal and Pathologic Brain. Nature Neuroscience, 10, 1387-1394.

[209]   Ryu, K.Y., Cho, G.S., Piao, H.Z. and Kim, W.-K. (2012) Role of TGF-β in Survival of Phagocytizing: Autocrine Suppression of TNF-α Production and Oxidative Stress. Experimental Neurobiology, 21, 151-157.

[210]   Doyle, K.P., Cekanaviciute, E., Mamer, L.E. and Buckwalter, M.S. (2010) TGF β Signaling in the Brain Increases with Aging and Signals to Astrocytes and Innate Immune Cells in the Weeks after Stroke. Journal of Neuroinflammation, 7, 62.

[211]   Woods, S.C., Porte, D. Jr., Bobbioni, E., Ionescu, E., Sauter, J.F., Rohner-Jeanrenaud, E. and Jeanrenaud, B. (1985) Insulin: Its Relationship to the Central Nervous System and to the Control of Food Intake and Body Weight. The American Journal of Clinical Nutrition, 42, 1063-1071.

[212]   Marks, J.L., Porte, D. Jr., Stahl, W.L. and Baskin, D.G. (1990) Localization of Insulin Receptor mRNA in Rat Brain by in Situ Hybridization. Endocrinology, 127, 3234-3236.

[213]   Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M.J. and Alkon, D.L. (1999) Brain Insulin Receptors and Spatial Memory. Correlated Changes in Gene Expression, Tyrosine Phosphorylation, and Signaling Molecules in the Hippocampus of Water Maze Trained Rats. The Journal of Biological Chemistry, 274, 34893-34902.

[214]   Woods, S.C., Seeley, R.J., Baskin, D.G. and Schwartz, M.W. (2003) Insulin and the Blood-Brain Barrier. Current Pharmaceutical Design, 9, 795-800.

[215]   Plum, L., Schubert, M. and Brüning, J.C. (2005) The Role of Insulin Receptor Signaling in the Brain. Trends in Endocrinology and Metabolism, 16, 59-65.

[216]   Lee, S.H., Zabolotny, J.M., Huang, H., Lee, H. and Kim, Y.-B. (2016) Insulin in the Nervous System and the Mind: Functions in Metabolism, Memory, and Mood. Molecular Metabolism, 5, 589-601.

[217]   Kuusisto, J., Koivisto, K., MyKK?nem, L., Helkala, E.L., Vanhanen, M., H?nninen, T., Kervinen, K., Kes?niemi, Y.A., Riekkinen, P.J. and Laakso, M. (1997) Association between Features of Insulin Resistance Syndrome and Alzheimer’s Disease Independently of Apolipoprotein E4 Phenotype: Cross Sectional Population Based Study. BMJ, 315, 1045-1049.

[218]   Watson, G.S. and Craft, S. (2003) The Role Insulin Resistance in the Pathogenesis of Alzheimer’s Disease: Implications for Treatment. CNS Drugs, 17, 27-45.

[219]   Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., et al. (2004) Role for Neuronal Insulin Resistance in Neurodegenerative Diseases. Proceedings of the National Academy of Sciences of the United States of America, 101, 3100-3105.

[220]   Craft, S. (2005) Insulin Resistance Syndrome and Alzheimer’s Disease: Age- and Obesity-Related Effects on Memory, Amyloid, and Inflammation. Neurobiology of Aging, 26, 65-69.

[221]   Neumann, K.F., Rojo, L., Navarrete, L.P., Farias, G., Reyes, P. and Maccioni, R.B. (2008) Insulin Resistance and Alzheimer’s Disease: Molecular Link & Clinical Implications. Current Alzheimer Research, 5, 438-447.

[222]   De la Monte, S.M. (2009) Insulin Resistance and Alzheimer’s Disease. BMB Reports, 42, 475-481.

[223]   Sj?strand, M. and Eriksson, J.W. (2009) Neurocrine Mechanisms in Insulin Resistance. Molecular and Cellular Endocrinology, 297, 104-111.

[224]   Mullins, R.J., Diehl, T.C., Chia, C.W. and Kapogiannis, D. (2017) Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 9, 118.

[225]   Arnold, S.E., Arvanitakis, Z., Macauley-Rambach, S.L., Koenig, A.M., Wang, H.-Y., Ahima, R.S., Craff, S., et al. (2018) Brain Insulin Resistance in Type 2 Diabetes and Alzheimer Disease: Concepts and Conundrums. Nature Reviews Neurology, 14, 168-181.

[226]   Anand, R., Gill, K.D. and Mahdi, A.A. (2014) Therapeutic of Alzheimer’s Disease: Past, Present and Future. Neuropharmacology, 76, 27-50.

[227]   Sutton, R., Keohane, M.E., VanderBerg, S.R. and Gonias, S.L. (1994) Plasminogen Activator Inhibitor-1 in the Cerebrospinal Fluid as an Index of Neurological Disease. Blood Coagulation & Fibrinolysis, 5, 167-171.

[228]   Oh, J., Lee, H.J., Song, J.H., Park, S.I. and Kim, H. (2014) Plasminogen Activator Inhibitor-1 as an Early Potential Diagnostic Marker for Alzheimer’s Disease. Experimental Gerontology, 60, 87-91.

[229]   Albo, D.R., Arnoletti, J.P., Castiglioni, A., Granick, M.S., Solomon, M.P., Rothman, V.L. and Tuszynski, G.P. (1994) Thrombospondin (TSP) and Transforming Factor Beta 1 (TGF-beta) Promote Human A549 Lung Carcinoma Cell Plasminogen Activator Inhibitor Type 1 (PAI-1) Production and Stimulate Tumor Cell Attachment in Vitro. Biochemical and Biophysical Research Communications, 203, 857-865.

[230]   Dennier, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., Gauthier, J.M., et al. (1998) Direct Binding of Smad3 and Smad4 to Critical TGF Beta-Inducible Elements in the Promoter of Human Plasminogen Activator Inhibitor-Type 1 Gene. The EMBO Journal, 17, 3091-3100.

[231]   Samarakoon, R., Higgins, C.E., Higgins, S.P., Kutz, S.M. and Higgins, P.J. (2005) Plasminogen Activator Inhibitor Type 1 Gene Expression and Induced Migration in TGF-Beta 1-Stimulated Smooth Muscle Cells Is pp60(c-src)/ MEK-Dependent. Journal of Cellular Physiology, 204, 236-246.

[232]   Vivien, D. and Buisson, A. (2000) Serine Protease Inhibitors: Novel Therapeutic Targets for Stroke. Journal of Cerebral Blood Flow & Metabolism, 20, 755-764.

[233]   Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheime’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356.

[234]   Higgins, P.J. (2006) The TGF-β1/Upstream Stimulatory Factor-Regulated PAI-1 Gene: Potential Involvement and a Therapeutic Target in Alzheimer’s Disease. Journal of Biomedicine and Biotechnology, 2006, Article ID: 15792.

[235]   Cesari, M., Pahor, M. and Incalzi, R.A. (2010) Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions. Cardiovascular Therapeutics, 28, e72-e91.

[236]   Akhhter, H., Katre, A., Li, L., Liu, X. and Liu, R.M. (2011) Therapeutic Potential and Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer’s Disease. Journal of Alzheimer’s Disease, 26, 767-778.

[237]   Tj?mlund-Wolf, A., Brogren, H., Lo, E.H. and Wang, X. (2012) Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases. Stroke, 43, 2833-2839.

[238]   Kutz, S.M., Higgins, C.E. and Higgins, P.J. (2012) Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer’s Disease. Molecular Medicine, 1, 106-110.

[239]   Aprahamian, I., Stella, F. and Forlenza, O. (2013) New Treatment Strategies for Alzheimer’s Disease: Is There a Hope? Indian Journal of Medical Research, 138, 449-460.

[240]   Yildiz, S.Y., Kuru, P., Oner, E.T. and Agirbasli, M. (2014) Functional Stability of Plasminogen Activator Inhibitor-1. The Scientific World Journal, 2014, Article ID: 858293.

[241]   Mannarino, E., Pasqualini, L., Ciuffetti, G. and Lombardini, R. (1992) Effect of Oral Administration of Sulodexide on Fibrinolysis and Plasma Viscosity: A Pilot Study. Drug Investigation, 4, 346-350.

[242]   Cocchery, S. and Mannello, F. (2014) Development and Use of Sulodexide in Vascular Diseases: Implications for Treatment. Drug Design, Development and Therapy, 8, 49-65.

[243]   Baluta, M.M. and Vintila, M.M. (2015) PAI-1 Inhibition-Another Therapeutic Option for Cardiovascular Protection. Maedica, 10, 147-152.

[244]   Lasierra Cirujeda, J., Aza Pascual-Salcedo, M.J. and Aza Pascual-Salcedo, M.M. (2016) Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study. World Journal of Cardiovascular Disease, 6, 54-71.

[245]   Lasierra-Cirujeda, J., Coronel, P., Aza Pascual-Salcedo, M.J., Gimeno, M., Aza Pascual-Salcedo, M.M., Lasierra-Iba?ez, A. and Lasala-Aza, C. (2018) Stress/Inflammation and PAI-1 as Stellar Processes in the Aging and Associated Pathologies. Integrative Molecular Medicine, 5, 1-2.